NAV Facilities Gain Momentum Among Alternatives Funds
28.2.2023 11:00:00 EET | Business Wire | Press release
Growth in Net Asset Value (NAV) credit facilities has increased exponentially in importance among private equity and other alternative investment funds since the pandemic relative to the secondary trading of assets as a means of creating liquidity, according to the Citco group of companies (Citco).
The NAV credit facility, a little-known institutional financial product, experienced approximate 30% annual growth across Citco’s client base between 2019 and 2022, while secondary trading grew at an approximate 7% annual rate over the same period. At times, institutional investors have used NAV loans in lieu of a sale of assets on the secondary market as the latter could result in a loss. However, the NAV Facility is now growing in importance as it has the benefit of generating interim liquidity, allowing the assets to be realized in an orderly manner over time. In turn, asset sales have become challenging as central banks worldwide tighten financial conditions: the exit – or sale of assets – to investment ratio for private equity firms hit a 10-year low in 2022 (Pitchbook, 2022).
A NAV facility is most often a loan – extended by banks, insurance companies and specialty private lenders – to an alternative investment fund that is secured by the fund’s investments, which collectively comprise its NAV. These investments may consist of private equity, venture capital, infrastructure, credit, real estate or holdings in other investment funds.
The current size of NAV facilities globally is estimated to be less than $100Bn (The Fund Finance Association, 2022), which represents under 1% of the estimated value of private capital investments. Based on current growth rates, Citco estimates the NAV market could grow to over $600Bn by 2030.
Michael Peterson, Managing Director of Citco Capital Solutions Inc., said: “During the 2008 financial crisis, NAV facilities were primarily used for fund-of-funds, which are investment vehicles that pool capital and invest in underlying strategies managed by third-parties. Unlike leveraged loans, high-yield bonds or residential mortgages, NAV facilities enjoyed favorable credit outcomes during the crisis, with minimal defaults and losses.
“For alternative asset managers, a prudently structured NAV facility provides liquidity, helping a manager to fulfill its fiduciary duty to its investor clients. For lenders, they provide a secure, low loan-to-value credit structure with a diversified collateral pool and favorable alignment of interests. Systemically, these facilities serve as a safety valve for alternative investment vehicles, facilitating the efficient allocation of capital that underpins the global economy.
“When we look at the performance of our clients during the financial crises, they experienced favorable outcomes. Moreover, we believe NAV loans provide a good risk adjusted investment for the lender. While NAV lending is an evolving segment of alternative asset lending with expanding demand, we believe it serves an important need and there are key structural protections for lenders, borrowers and the broader system.”
Typically, funds borrow to generate liquidity and deploy additional capital after the commitments from their investors are exhausted. This may be due to an unforeseen extreme event - such as the Covid pandemic - requiring them to support existing investments, or they may seek to take advantage of lucrative follow-on investment opportunities.
An alternative use of a NAV loan is when institutional investors seek incremental leverage on their Limited Partnership (LP) holdings in alternative funds. Typically, the investor submits a subset of their alternative investment holdings to a lender as collateral for a NAV loan, thus creating liquidity. Historically, institutional investors have tended to use this type of loan in order to generate liquidity when the cash flow from their LP portfolio is expected to slow.
NAV lenders tend to be conservative in their structuring and underwriting, and rely on several features of the facilities to protect themselves:
- First and foremost, they are low leverage - usually between 5% and 25% of the fund’s value. By looking at historical data, including investment performance during and after the great financial crisis, lenders size facilities with a requisite margin of safety to ensure the borrower can withstand a severe downturn. Across Citco’s client base, it has seen advance rates range from 3% to 20% of eligible collateral.
- Second, unlike a leveraged loan to a company sponsored by a private equity firm, a NAV facility’s collateral consists of a diversified pool of investments, typically a dozen or more individual positions. This diversification protects the lender against idiosyncratic shocks at the portfolio level.
- Third, the maturity of the facilities are typically matched with the expected liquidation timeframe of the underlying assets. Unlike products which engage in maturity transformation, there is no risk of a “run on the bank”.
- Lastly, these facilities benefit from a structural alignment of interests: both the fund sponsor – the asset manager – and its investors are fully subordinated to the NAV lender in priority of payment. For an asset manager to continue its main business of raising future capital, it would be disastrous to default on a NAV facility. Though private equity managers are notoriously clever game theorists when dealing with lenders, every manager understands that fundraising is a repeated game. Similarly, the fund borrower shares an alignment with the lender in that a default would create a number of structural and reputational issues for its investors.
--ENDS--
For more information, please visit: https://www.citco.com/our-services/direct-lending-and-capital-advisory
About the Citco group of companies (Citco)
The Citco group of companies (Citco) is a network of independent companies worldwide. These companies are leading providers of asset-servicing solutions to the global alternative investment industry. With over $1.8 trillion in assets under administration and operations spanning across 36 countries, Citco’s unique culture of innovation and client-driven solutions have provided Citco’s clients with a trusted partner for more than four decades. Having grown organically into one of the largest asset servicers in the industry, Citco’s Fund Services companies offer a full suite of middle office and back office services including, treasury and loan handling, daily NAV calculations and investor services, corporate and legal services, regulatory and risk reporting as well as tax and financial reporting services. Investing heavily in innovation and technology whilst further developing its current suite of client-friendly solutions, Citco will continue into the future as a flagbearer for the asset-servicing industry.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230228005134/en/
Contact information
citco@instinctif.com
Nick Corrin / Emma Baxter at Instinctif Partners
+44 (0) 20 7457 2057 / +44 (0) 207 457 2868
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Announces FDA IND Clearance for Partner NEOK Bio’s NEOK002 Targeting Solid Tumors27.3.2026 02:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that its partner NEOK Bio, Inc. recently received clearance from the U.S. Food and Drug Administration (FDA) of an investigational new drug (IND) application for NEOK002, an EGFR/MUC1-targeting ADC program for solid tumors. NEOK Bio plans to initiate a Phase 1 clinical study in the second quarter of 2026 and expects to report initial data in 2027. This IND clearance marks an important milestone for NEOK002, an EGFR/MUC1-targeting ADC candidate developed by NEOK Bio and built on a bispecific antibody originally developed by Biocytogen and licensed in 2024. According to NEOK Bio, NEOK002 is being advanced for solid tumors and may offer differentiated efficacy and safety compared with monospecific ADC approaches directed at either target alone. Dr. Yuelei Sh
Spring is in Full Bloom at the Empire State Building with New Festive Experiences, Sweet Treats, and Seasonal Tower Lighting26.3.2026 22:30:00 EET | Press release
Spring is in full swing at the “World’s Most Famous Building.” The Empire State Building (ESB) today announced a vibrant lineup of spring events in NYC, which include special experiences, treat pop-ups, and an iconic tower lighting that captures the joy and color of the beautiful season. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260326216271/en/ Spring is in Full Bloom at the Empire State Building with New Festive Experiences, Sweet Treats, and Seasonal Tower Lighting “The Empire State Building Observation Deck has transformed into a celebration of the season and one of the best things to do in NYC this spring,” said Dan Rogoski, observatory general manager. “Whether it’s views beside our butterfly installation, sweet pop-ups, or a chance to spot the Easter Bunny, there is something special for every visitor.” Flutter of Color: The Empire State Building installed a brand-new photo opportunity on the 86th Floor Observati
Venture Global and Edison Announce Calcasieu Pass Arbitration Settlement26.3.2026 22:15:00 EET | Press release
Today, Venture Global and Edison jointly announced the signature of a commercial agreement for the settlement of the pending arbitration between the two companies concerning the Calcasieu Pass project. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260326559130/en/ Completion of the settlement is expected by the end of Q2 2026, at which point the arbitration will be terminated. The agreement fully resolves the arbitration in its entirety. As part of the settlement, Edison and Venture Global have also agreed to the delivery to Europe of additional cargoes beyond those envisaged under the long-term contract, to support gas supplies primarily to the Italian market. The first delivery is scheduled for May 2026, in Italy, at the Adriatic LNG Terminal. The agreement represents a significant step in strengthening commercial cooperation between the parties and it establishes a foundation for further future deliveries in the context
Reply Recognized as a Microsoft Frontier Partner for Enterprise AI Delivery26.3.2026 20:06:00 EET | Press release
Reply [EXM, STAR: REY] announces it has been recognized as a Microsoft Frontier Partner within the Microsoft AI Cloud Partner Program, earning the Frontier Partner Badge for demonstrating advanced capabilities in delivering AI-first solutions across Cloud & AI Platforms, AI Business Solutions, and Security. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260326965586/en/ The recognition reflects Reply’s capabilities across the Microsoft ecosystem, built through the work of its specialized companies – including Aim Reply, Business Elements Reply, Cluster Reply, Root16 Reply, Solidsoft Reply, Valorem Reply, WM Reply and Zest Reply – supporting enterprise organizations in designing, implementing, and operating AI solutions on Microsoft platforms across real-world business scenarios. The Frontier Partner badge recognizes partners that demonstrate advanced AI driven capabilities and meet rigorous badge requirements at the time of
InterSystems nimittänyt terveydenhuoltotoiminnan johtajaksi tohtori Tim Ferrisin, entisen NHS- ja Mass General ‑johtajan26.3.2026 20:00:00 EET | Tiedote
InterSystems on luovien datateknologiaratkaisujen tarjoaja, jonka ratkaisuihin on tallennettu yli miljardi terveystietotietuetta maailmanlaajuisesti. Yritys ilmoitti tänään nimittäneensä terveydenhuoltotoiminnan johtajaksi lääketieteen tohtori Tim Ferrisin. Nimityksestä ilmoitettiin samaan aikaan, kun terveydenhuoltoalan johtajat kokoontuvat vuoden 2026 HIMSS Global Health Conference & Exhibition ‑tapahtumaan. Roolissaan Ferris pääsee soveltamaan kattavaa toimialakokemustaan, kun hän ohjaa yrityksen terveydenhuoltoratkaisujen kliinistä ja strategista suuntaa maailmanlaajuisesti. Laajan kokemuksensa turvin hän toimii maailmanlaajuisten terveydenhuoltojärjestelmien ja hallitusten strategisena neuvonantajana ja suunnittelee räätälöityjä teknologiaratkaisuja, jotka perustuvat todellisiin johtotason tarpeisiin. Samalla hän edistää akateemista tutkimustaan terveysdata-arkkitehtuurista sekä johtaa julkista keskustelua tekoälyn ja hoidon tarjoamisen yhdistämisestä. Ferris tuo InterSystemsiin a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
